PK Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to
Patients With Advanced Solid and Hematologic Tumors
This is an open-label non-randomized pharmacokinetic (PK) study of Homoharringtonine
(Omacetaxine Mepesuccinate) administered as a subcutaneous (SC)injection to patients with
relapsed and/or refractory hematologic malignancies and to patients with advanced solid
tumors with no bone marrow involvement.
- Be ≥18 years old.
- Be diagnosed with relapsed or refractory leukemia including chronic myelogenous
leukemia (CML), acute promyelocytic leukemia (APL), acute myelogenous leukemia (AML),
or myelodysplastic syndrome (MDS)
- Relapsed defined as reappearance of leukemic blasts in the peripheral blood or
the finding of ≥5% blasts in the bone marrow, not attributable to another cause
(e.g., bone marrow regeneration after consolidation therapy).
- Refractory defined as no response to previous combined chemotherapy regimens
including at least one cytarabine plus one anthracycline advanced solid tumors
(i.e., breast, lung, head / neck, colorectal, melanoma, and sarcoma). Patients
must have exhausted or become intolerant to all available therapies.
- (Patients with hematologic malignancies): Have completed all previous anti-leukemic
therapy (except leukapheresis) at least 2 weeks prior to the first planned dose of
OMA and must have fully recovered from side effects of a previous therapy unless,
disease progression necessitates early therapy. Leukapheresis is allowed up to 24
hours prior to registration.
- (Patients with solid tumors): Patients may have measurable or unmeasurable disease.
Measurable disease is defined as at least one lesion that can be accurately measured
in at least one dimension (longest diameter to be recorded) as ≥20 mm with
conventional computerized tomography (CT) or magnetic resonance imaging (MRI) scans,
or as ≥10 mm with spiral computerized tomography (CT) scan. Imaging must be performed
within 28 days of the first dose of study drug.
- Have an estimated life expectancy of ≥12 weeks
- Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤2 (see
- Be able to provide written informed consent prior to enrollment into the study. In
the event that the patient is re-screened for study participation or a protocol
amendment alters the care of an ongoing patient, a new informed consent form must be
- Be male or a non-pregnant, non-lactating female. Fertile patients must agree to use
an effective barrier method contraception (e.g., latex condom, diaphragm, or cervical
cap) to avoid pregnancy while on therapy and for 6 months following the
discontinuation of the study drug.
- A non-fertile female is defined as:
- Postmenopausal (amenorrheic for ≥12 months) Undergone a complete oophorectomy or
- Have a negative serum pregnancy test within 7 days prior to the first dose of study
drug (if patient is a female of childbearing potential).
- QTc <450 ms on screening 12-lead ECG (using Bazett's correction of QT interval
- Have adequate organ function as indicated by the following laboratory values obtained
within 7 days prior to the first dose of study drug as outlined in Table 3.
- Be able and willing to comply with the requirements of the entire study.
- Received previous treatment with OMA within 6 months of study entry.
- Have New York Heart Association (NYHA) Class 3 or 4 heart disease, active ischemia,
or any uncontrolled, unstable cardiac condition for which treatment for the condition
is indicated but is not controlled despite adequate therapy, including angina
pectoris, cardiac arrhythmia, hypertension, or congestive heart failure (see Appendix
- Experienced a myocardial infarction in the previous 12 weeks.
- Have solid tumors with known bone marrow or central nervous system (CNS) involvement.
- Have an active, uncontrolled systemic infection considered opportunistic, life
threatening, or clinically significant at the time of treatment.
- Are pregnant or lactating.
- Received systemic chemotherapy in the 4 weeks prior to first dose of study drug,
unless treatment is required for progressive leukemia. In patients with rapidly
proliferating disease, hydroxyurea may be administered immediately prior to and
during the first two cycles of treatment, if clinically indicated, to control
- Received radiation therapy within 6 weeks of the first dose of study drug. Localized
radiation for palliation may be administered with 2 weeks of the first dose of study
- Have any medical condition or psychiatric disorder(s) rendering the patient unable to
understand the nature, scope, and possible consequences of the study.